Oral VTX3232 Study Reveals Significant Reductions in Inflammatory Cardiovascular Risk Markers

Ventyx Biosciences' VTX3232 demonstrates significant reduction in heart disease risk markers in Phase 2 trial, with strong anti-inflammatory effects and good safety profile.